-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-1005 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-1005 in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-1005 in Parkinson's Disease Drug Details: Gene therapy is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-2618 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-2618 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2618 in Melanoma Drug Details: TQB-2618 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carfostin in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carfostin in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carfostin in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carfostin in Non-ischemic Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carfostin in Non-ischemic Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carfostin in Non-ischemic Cardiomyopathy Drug Details: Carfostin (BNP-CHF) is under development for...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewCardiomyopathy – Drugs In Development, 2024
Empower your strategies with our Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Cardiomyopathy a disease of the heart muscle, where the walls of the heart chambers have become stretched, thickened or stiff. This affects the heart's ability to pump blood around the body. Most types of cardiomyopathy are inherited. It can also be caused by other conditions, or risk factors, but for some people the cause is unknown. Cardiomyopathy can affect people of all ages...
-
Product Insights
NewLimb-Girdle Muscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Limb-Girdle Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Limb-girdle muscular dystrophy encompasses a spectrum of disorders impacting the voluntary muscles encircling the hips and shoulders, exhibiting equal prevalence in males and females. The majority of these dystrophies follow an autosomal recessive inheritance pattern, although some rarer forms adhere to an autosomal dominant model. With over 20 recognized types, this condition arises from genetic material (DNA) alterations and can manifest...
-
Product Insights
NewMultiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2024
Empower your strategies with our Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2024 report and make more profitable business decisions. Multiple system atrophy (MSA), or Shy-Drager syndrome, is a neurological disorder that impairs the body's involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications. The Multiple System Atrophy (MSA or Shy-Drager...
-
Product Insights
NewHuntington Disease – Drugs In Development, 2024
Empower your strategies with our Huntington Disease – Drugs In Development, 2024 report and make more profitable business decisions. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington...